Viability study of a multiplex diagnostic platform for Chagas disease

Area of Science:

• Immunology
• Parasitology
• Biotechnology

Background:

• Chagas disease diagnosis relies on detecting Trypanosoma cruzi infection.
• Current diagnostic methods may have limitations in sensitivity and specificity.
• Development of advanced diagnostic platforms is crucial for effective disease management.

Purpose of the Study:

• To evaluate a new multiplex assay platform for Trypanosoma cruzi detection.
• To assess the performance of recombinant antigens (CRA, FRA, CRAFRA) and parasite lysate.
• To compare multiplex assay performance against singleplex tests.

Main Methods:

• Utilized a multiplex assay platform with recombinant antigens CRA, FRA, CRAFRA, and T. cruzi lysate.
• Evaluated antigen performance in singleplex and duplex test formats.
• Compared assay sensitivity and specificity using positive and negative serum samples.

Main Results:

• Recombinant protein CRA showed lower sensitivity (55%) in singleplex tests.
• Antigens FRA, CRAFRA, and T. cruzi lysate demonstrated 100% sensitivity and specificity in singleplex.
• The duplex test with CRAFRA/T. cruzi lysate achieved 100% specificity and sensitivity with a lower cut-off value.
• Multiplex formats increased sensitivity and specificity without interference between bead sets.

Conclusions:

• Multiplex assays offer a promising alternative to singleplex detection for Chagas disease.
• The CRAFRA/T. cruzi lysate duplex combination shows superior diagnostic performance.
• Multiplex diagnostic tools are essential for enhancing sensitivity and specificity in disease detection.